

PROLIGHT DIAGNOSTICS PUBLISHES INVESTOR LETTER FOR DECEMBER 2024

In 2024, Prolight has achieved many business-critical milestones, positioning the company optimally for 2025 and on track for its planned commercial launch in 2026.

link to the investor letter: <https://prolightdx.com/PRLD-Investerarbrev-dec-2024-EN.pdf>

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.

We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

[Prolight Diagnostics publishes investor letter for December 2024](#)